Torneos instantáneos de futbol en cualquier parte del mundo propuesta de implementación de una aplicación web que permite la generación y la administración de torneos de todos los equipos involucrados que se enfrentan entre sí y elige un ganador a través de la acumulación de puntos

The present thesis project consists in the development of a web application in the Python programming language and Django framework to control the generation and administration of soccer tournaments with access from any Internet browser around the world. The application provides a super administrator created by the system and a module to register any users using an independent platform. For this application, four functionalities were developed: user registration, user creation with privileges, tournament creations, and computations to determine a champion in tournaments in league format. The computations provide a standings table in which is ordered by points, goal difference and goals in favor respectively. The application allows to differentiate many types of users. There is the user that inputs data to update the scores of the matches from a tournament it was assigned. There is the user's team representative who can view only the standings of the team it was assigned to. Lastly, there are public tournaments that can be viewed by any type of user without registration.El presente proyecto de tesis trata de la creación de una aplicación web en lenguaje de programación Python y la ayuda del Framework Django, para controlar la generación y administración de torneos de fútbol con acceso desde cualquier parte del mundo desde cualquier explorador de internet. La aplicación provee un súper administrador creado por el sistema y un módulo para registrar usuarios que deseen utilizar la plataforma de forma independiente. Para esta aplicación se implementaron cuatro funcionalidades: registro de usuarios, creación de usuarios y asignación de permisos, creación de torneos y cálculos realizados para definir un ganador del torneo en formato de liga. Los cálculos realizados proporcionan una tabla de posiciones por torneo en la cual se ordenan los equipos por puntos, diferencia de goles y goles a favor respectivamente. La aplicación permite diferenciar tipos de Usuarios. Existe el usuario digitador que tiene el permiso de actualizar los resultados de los partidos del torneo que fue asignado. Existe el usuario representante de equipo que podrá ver únicamente la tabla de posiciones del equipo al cual fue asignado. Por último, existen torneos públicos los cuales podrán ser vistos por cualquier persona con acceso a internet sin tener que registrarse

Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo

BACKGROUND: Cardiovascular (CV) disease is the leading cause of morbidity and mortality in patients with type 2 diabetes mellitus (T2DM). Furthermore, patients with T2DM and acute coronary syndrome (ACS) have a particularly high risk of CV events. The glucagon-like peptide 1 receptor agonist, lixisenatide, improves glycemia, but its effects on CV events have not been thoroughly evaluated. METHODS: ELIXA (www.clinicaltrials.gov no. NCT01147250) is a randomized, double-blind, placebo-controlled, parallel-group, multicenter study of lixisenatide in patients with T2DM and a recent ACS event. The primary aim is to evaluate the effects of lixisenatide on CV morbidity and mortality in a population at high CV risk. The primary efficacy end point is a composite of time to CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for unstable angina. Data are systematically collected for safety outcomes, including hypoglycemia, pancreatitis, and malignancy. RESULTS: Enrollment began in July 2010 and ended in August 2013; 6,068 patients from 49 countries were randomized. Of these, 69% are men and 75% are white; at baseline, the mean ± SD age was 60.3 ± 9.7 years, body mass index was 30.2 ± 5.7 kg/m(2), and duration of T2DM was 9.3 ± 8.2 years. The qualifying ACS was a myocardial infarction in 83% and unstable angina in 17%. The study will continue until the positive adjudication of the protocol-specified number of primary CV events. CONCLUSION: ELIXA will be the first trial to report the safety and efficacy of a glucagon-like peptide 1 receptor agonist in people with T2DM and high CV event risk